Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Goodwill (2018 - 2025)

Historic Goodwill for Akebia Therapeutics (AKBA) over the last 8 years, with Q3 2025 value amounting to $59.0 million.

  • Akebia Therapeutics' Goodwill changed 0.0% to $59.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $59.0 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Akebia Therapeutics reported Goodwill of $59.0 million as of Q3 2025, which was down 0.0% from $59.0 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Goodwill peaked at $59.0 million during Q4 2021, and registered a low of $55.1 million during Q1 2021.
  • Over the past 5 years, Akebia Therapeutics' median Goodwill value was $59.0 million (recorded in 2021), while the average stood at $58.4 million.
  • Within the past 5 years, the most significant YoY rise in Akebia Therapeutics' Goodwill was 715.79% (2021), while the steepest drop was 0.0% (2021).
  • Quarter analysis of 5 years shows Akebia Therapeutics' Goodwill stood at $59.0 million in 2021, then changed by 0.0% to $59.0 million in 2022, then changed by 0.0% to $59.0 million in 2023, then changed by 0.0% to $59.0 million in 2024, then changed by 0.0% to $59.0 million in 2025.
  • Its Goodwill was $59.0 million in Q3 2025, compared to $59.0 million in Q2 2025 and $59.0 million in Q1 2025.